Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin
Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma and SGX302 for the Treatment of Psoriasis
Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma and SGX302 for the Treatment of Psoriasis
Please help local businesses by taking an online survey to help us navigate through these unprecedented times. None of the responses will be shared or used for any other purpose except to better serve our community. The survey is at: www.pulsepoll.com $1,000 is being awarded. Everyone completing the survey will be able to enter a contest to Win as our way of saying, "Thank You" for your time. Thank You!